Table 3.
Risk of Parkinson’s disease associated with duration and regularity of calcium-channel blocker use
| # cases | Person-years | RR (95% CI) | p-value | |
|---|---|---|---|---|
| Never users of CCBs | 444 | 1910678 | REF | |
| CCB users | ||||
| Past | 28 | 56344 | 1.23 (0.83, 1.81) | 0.31 |
| Current, <4 yrs | 21 | 65515 | 1.06 (0.68, 1.65) | 0.80 |
| Current, >=4 yrs | 21 | 54141 | 1.05 (0.67, 1.65) | 0.83 |
| Never users of CCBs | 444 | 1910678 | REF | |
| Use of CCBs | ||||
| Irregular | 37 | 96151 | 1.17 (0.83, 1.64) | 0.37 |
| Regular, >= 4yrs | 33 | 79849 | 1.03 (0.73, 1.46) | 0.85 |
The referent (never users) are those who did not report use of CCBs on any questionnaire cycle prior to censoring. This includes individuals who did not use any anti-hypertensives and those who used anti-hypertensives other than calcium channel blockers.
Adjusted for age and pack-years of smoking